{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:42Z","timestamp":1790361702620,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>A retrospective review of patients with liver metastases from cutaneous or uveal melanoma treated with yttrium-90 (Y90), chemoembolization (CE), or percutaneous hepatic perfusion (PHP) was conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty patients (6 Y90, 10 PHP, 12 CE, 1 PHP then Y90, 1 CE then PHP) were included. Multivariate analysis showed improved HPFS for PHP versus Y90 (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.004), PHP versus CE (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.02) but not for CE versus Y90. PFS was also significantly different: Y90 (54 d), CE (52 d), PHP (245 d), <jats:italic toggle=\"yes\">P<\/jats:italic>=0.03. PHP treatment and lower tumor burden were significant predictors of prolonged PFS on multivariate analysis. Median OS from time of treatment was longest, but not significant, for PHP at 608 days versus Y90 (295 d) and CE (265 d), <jats:italic toggle=\"yes\">P<\/jats:italic>=0.24. Only PHP treatment versus Y90 and lower tumor burden had improved OS on multivariate analysis (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.03, 0.03, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>HPFS and PFS were significantly prolonged in patients treated with PHP versus CE or Y90. Median OS in PHP patients was over double that seen in Y90 or CE patients but was significant only between PHP and Y90.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000356","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T05:06:16Z","timestamp":1483679176000},"page":"747-753","source":"Crossref","is-referenced-by-count":29,"title":["Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Andrea M.","family":"Abbott","sequence":"first","affiliation":[{"name":"Cutaneous Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Doepker","sequence":"additional","affiliation":[{"name":"Cutaneous Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Perez","sequence":"additional","affiliation":[{"name":"Cutaneous Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Gandle","sequence":"additional","affiliation":[{"name":"Cutaneous Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsung","family":"Choi","sequence":"additional","affiliation":[{"name":"Interventional Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Shridhar","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[{"name":"Cutaneous Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.iio.0000195852.08453.de","article-title":"Metastatic uveal melanoma therapy: current options","volume":"46","author":"Hu","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jso.20079","article-title":"The natural course of cutaneous melanoma","volume":"86","author":"Leiter","year":"2004","journal-title":"J Surg Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","article-title":"Survival of patients with metastases from uveal melanoma","volume":"98","author":"Gragoudas","year":"1991","journal-title":"Ophthalmology"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ohc.2004.07.003","article-title":"Metastatic uveal melanoma","volume":"18","author":"Singh","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jso.23501","article-title":"Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience","volume":"109","author":"Forster","year":"2013","journal-title":"J Surg Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.28480","article-title":"Metastatic melanoma to the liver. A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options","volume":"120","author":"Agarwala","year":"2014","journal-title":"Cancer"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/bjo.2008.153684","article-title":"Long-term survival of uveal melanoma patients after surgery for liver metastasis","volume":"93","author":"Frenkel","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1245\/ASO.2004.07.004","article-title":"Regional treatment options for patients with ocular melanoma metastatic to the liver","volume":"11","author":"Feldman","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1245\/s10434-013-3304-z","article-title":"Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit","volume":"21","author":"Olofsson","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1745-6215-15-317","article-title":"Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial","volume":"15","author":"Olofsson","year":"2014","journal-title":"Trials"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1517\/17425255.2011.609555","article-title":"Minimally invasive intra-arterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion","volume":"7","author":"Han","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R15-20230903","first-page":"311","article-title":"Yttrium-90 radioembolization using Therasphere in the management of primary and secondary liver tumors","volume":"53","author":"Riaz","year":"2009","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/CMR.0000000000000051","article-title":"Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience","volume":"24","author":"Memon","year":"2014","journal-title":"Melanoma Res"},{"key":"R17-20230903","article-title":"Selective internal Yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: safety and efficacy cohort study","author":"Xing","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2214\/AJR.10.4881","article-title":"Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience","volume":"196","author":"Gonsalves","year":"2011","journal-title":"AJ Am J Roentgenol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/07357900802620893","article-title":"A first report of radioembolization for hepatic metastases from ocular melanoma","volume":"27","author":"Kennedy","year":"2009","journal-title":"Cancer Invest"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.3748\/wjg.v21.i27.8271","article-title":"Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors","volume":"21","author":"Kuei","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1517\/17425255.2014.951330","article-title":"Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion","volume":"10","author":"Rashid","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R22-20230903","first-page":"1","article-title":"Results of a randomized controlled multi-center phase III trial of percutaneous hepatic perfusion compared to best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/COC.0b013e3181b4b065","article-title":"Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors","volume":"33","author":"Gupta","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/07357907.2010.535052","article-title":"Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma","volume":"29","author":"Ahrar","year":"2011","journal-title":"Cancer Invest"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008390-200508000-00011","article-title":"Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study","volume":"15","author":"Patel","year":"2005","journal-title":"Melanoma Res"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e328334c36e","article-title":"Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome","volume":"20","author":"Schuster","year":"2010","journal-title":"Melanoma Res"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2214\/AJR.07.2675","article-title":"Hepatic arterial chemoembolization for management of metastatic melanoma","volume":"190","author":"Sharma","year":"2008","journal-title":"AJR Am J Roentgenol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201808000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:06:29Z","timestamp":1693710389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201808000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000356","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}